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Abstract 
Ovarian cancer is a leading cause of gynecological cancer-related death in Canadian 
women. Ovarian cancer is managed through surgical cytoreduction and carboplatin-based 
chemotherapy. Unfortunately, most patients often relapse or have reduced responses to 
initial chemotherapy. The mechanisms behind carboplatin resistance are poorly 
understood. In pilot studies, our group has observed vascular proliferation in patient 
samples following carboplatin treatment. The effectiveness of modulating 
neovascularization in combination with carboplatin has also been demonstrated in two 
large Phase 3 trials.  In this study, I explore the underlying mechanisms of chemotherapy-
induced vascular proliferation and potentially, tumour cell survival.  I hypothesize that 
carboplatin induces angiogenic factors in ovarian cancer cells leading to microvascular 
endothelial cell survival. 
To test my hypothesis, I screened for a variety of angiogenic factors in ovarian cancer 
cells and vascular endothelial cells following exposure to carboplatin. My results show 
that a number of angiogenic genes are upregulated in response to carboplatin exposure, 
including placental growth factor (PGF). Preclinical studies have shown that inhibition of 
PGF prevents tumour growth and metastasis. Therefore, I tested the effect of PGF and 
condition media prepared from ovarian cancer cells following carboplatin challenge on 
endothelial cell survival. My results show that PGF and ovarian cancer condition media 
facilitates endothelial cell survival. I also found that carboplatin may induce PGF 
expression in ovarian cancer cells through β-catenin activation. 
Findings from this study may help better understand the effects of carboplatin exposure 
on ovarian cancer. Furthermore, the results may provide additional targets to increase 
carboplatin sensitivity in ovarian cancer patients. 
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Chapter 1  
1 INTRODUCTION 
1.1 Ovarian cancer: the “silent killer” 
Ovarian cancer is the leading cause of death among gynecological malignancies in 
Canadian women1-3. The term “silent killer” is commonly used for ovarian cancer as it is 
often diagnosed at an advanced stage resulting in poor prognosis4. The high mortality 
rates associated with ovarian cancer is largely due to a general lack of understanding of 
the disease that leads to late-stage detection and diagnosis4. The etiology of ovarian 
cancer has been subject to ongoing debates and several mechanisms have been 
postulated. One proposed mechanism involved in the development of ovarian cancer is 
termed the “wear-and-tear” mechanism, where incessant ovulation causes the repeated 
destruction and repair of the ovarian surface epithelium (OSE)3,5 and tubal epithelial 
cells6. This repeated trauma to the OSE and fallopian tube during ovulation increases the 
likelihood of DNA damage and acquisition of carcinogenic mutations3. The trauma to the 
OSE and tubal epithelial cells is also shown to elicit an inflammatory response5,7. 
Ovulation also impacts the fallopian tube similarly by increasing DNA damage as well as 
evoking inflammatory responses6. Inclusion cysts may form within the ovarian cortex 
post-ovulation, where wound repair may increase the risk of genetic abnormalities and 
result in dysplastic changes in the epithelial cells8. Along with chronic inflammation, the 
increased level of different growth factors may drive the transformation of these 
epithelial cells towards malignant growth7. Lastly, it is also speculated that hormones 
secreted during menopause, including gonadotropins luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) may contribute to the development of ovarian 
cancer5,7,8. Gonadotropins among other hormones initiate ovulation, thus ovulation is 
often termed a hormone-induced injury9. The late onset of ovarian cancer in 60-62 year 
olds10 can perhaps be attributed to a lifetime of ovulatory cycles accompanied by the 
cyclic destruction of the OSE and fallopian tube epithelium, as well as changes in 
hormonal levels during these cycles and menopause. 
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1.2 Ovarian cancer: origin and clinical features 
According to the World Health Organization (WHO) Histological Classification, ovarian 
neoplasms are categorized by the most probable cell of origin, and the site of origin 
(ovary vs. fallopian tube) is under intense debate11. Over 80% of ovarian cancers are 
surface epithelial tumours, but ovarian cancer is also comprised of germ cell, sex cord-
stromal, and metastases categories11,12. Surface epithelial tumours are further classified 
by cell type: serous, mucinous, endometrioid, clear cell and undifferentiated. Due to a 
lack of early detection, most cases of ovarian cancer are diagnosed at a later, more 
aggressive stage known as high-grade serous ovarian carcinoma (HGSOC)13. HGSOCs 
are the most common histological subtype and are responsible for the most deaths from 
ovarian cancer14. Kurman and Shih (2010) have proposed a dualistic model which divides 
epithelial ovarian cancers into two broad groups (type I and II) based on genetic and 
morphological studies15,16. Molecularly, ovarian cancer is heterogeneous17. Low-grade 
surface epithelial tumours such as low grade serous carcinoma (LGSOC) are categorized 
as type I tumours, where morphology is distinct and tumours are genetically stable. 
Consistent mutations in type I tumours include Kirsten RAS oncogene homolog (KRAS), 
BRAF and/or ERBB25,16,18. These genes are all upstream regulators of mitogen-activated 
protein kinase (MAPK) which is believed to facilitate cell proliferation18. TP53 mutations 
are uncommon in type I tumours like LGSOC18. LGSOCs are slow growing and involve 
a step-wise progression from a serous cystadenoma or adenofibroma to a serous 
borderline tumour eventually progressing to an invasive micropapillary serous 
carcinoma18. Meanwhile, type II tumours can have a range of morphological patterns: 
papillary, glandular, and solid16. Type II HGSOCs are high grade, genetically unstable 
and involve several TP53 mutations, rapid growth and metastatic behaviour5,15,16. KRAS, 
BRAF or ERBB2 mutations are rare in HGSOCs18. In addition, approximately 10% of 
ovarian carcinomas are hereditary, where most involve BRCA mutations18. Other major 
genomic features of HGSOCs include copy number alterations (CNA), where the genome 
is altered by up to 46%, whereas LGSOCs have close to normal CNAs14.  
The most recent accepted origin of HGSOC is the fallopian tube16,19. Dutch investigators 
proposed the fallopian tube as the primary site for most type II ovarian cancers19. Small 
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primary lesions on the fallopian tube, termed serous tubal intraepithelial carcinoma 
(STIC), were reported in women that exhibited genetic predisposition for ovarian cancer 
development19. STIC was postulated to share a common origin with HGSOC tumours 
because the genomic signatures often harboured identical TP53 mutations20. In addition, 
over 70% of sporadic ovarian and peritoneal HGSOCs involved STIC16,21. In contrast, 
conclusive precursor lesions in ovaries have not been found5,16. Thus, the fallopian tube is 
believed to be the origin of ovarian cancer. It has been proposed that the invasive lesions 
found in the fallopian tube may shed malignant cells that implant on the ovary with 
subsequent tumour growth mimicking a primary ovarian tumour5. Some evidence 
supports that the tubal-peritoneal junction (TPJ), where the tubal lumen communicates 
with the peritoneal cavity, is the site of STIC origin22. This junction region is where the 
ciliated columnar epithelial lining of the tubal fimbriae meets the peritoneum, which is 
the serosal surface of the fallopian tube22. Risk-reducing salpingo-oophorectomy (RRSO) 
specimens from BRCA mutation carriers have also shown primary lesions of tubal 
origin23,24. In summary, due to the many different cell types involved in ovarian cancer, 
identifying the exact origin is difficult and possibly involves various sites. 
1.3 Ovarian cancer: current treatments 
The current treatment of ovarian cancer in most patients consists of debulking surgical 
resection of the primary tumour and platinum-based chemotherapy such as carboplatin, as 
well as a taxane drug, paclitaxel, commonly administered in a cyclic manner10,25. Some 
patients receive initial chemotherapy followed by debulking surgery and further 
chemotherapy10. Carboplatin is an alkylating agent, which consists of a platinum atom 
complexed with two ammonia groups and a cyclobutane-dicarboxyl residue26. 
Carboplatin dosage is measured by Calvert’s formula, which accounts for the area under 
concentration versus the time curve (AUC) and creatinine clearance, or renal function via 
determination of the glomerular filtration rate (GFR)26. It is most often used to treat 
gynecological cancers, head and neck as well as lung cancer27. Carboplatin undergoes 
activation inside the cell and forms reactive platinum complexes, covalently binding to 
DNA that causes intra- and inter-strand cross-linkages13,28. Activation of carboplatin 
inside the cell is through hydrolysis, resulting in a positively charged molecule which is 
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able to interact with nucleophilic molecules28. Carboplatin-induced modification of DNA 
inhibits replication and transcription leading to cell death13,28.  
Most patients are diagnosed at a late disease stage where the cancer has metastasized to 
adjacent pelvic organs and the peritoneal cavity. When diagnosed early, the 5-year 
survival rate with current treatment regimens is over 90%29, but the 5-year survival rate 
for late diagnosis (i.e. high grade stage) is approximately 15%30. However, despite 
positive response to initial chemotherapy, more than 80%29 of patients relapse after a 
period of improvement leading to a significant clinical challenge31. Recurrent disease 
which is unresponsive to chemotherapy treatment is the primary cause of mortality in 
HGSOC patients32. Intratumoral heterogeneity and selection of chemo-resistant subclones 
may account for chemotherapy resistance32. Mechanisms attributing to acquired 
resistance from platinum-based chemotherapy have been recently proposed. These 
include reversion of BRCA1 and BRCA2 mutations, and upregulation of AKT signalling, 
which ultimately leads to tumour cell survival32. Understanding the mechanisms 
underlying carboplatin failure is under intensive investigation. Within the last ten years, 
targeting angiogenesis for therapy is on the rise in combination with chemotherapy 
treatments. 
1.4 Physiological and pathological angiogenesis 
Angiogenesis, the sprouting of new blood vessels from existing ones, is well established 
to occur during embryonic development, and during the female reproductive cycle and 
wound healing33. Conditions such as psoriasis and rheumatoid arthritis are also dependent 
on angiogenesis34. During embryonic development, endothelial cells are initially derived 
de novo from precursor cells in a process termed vasculogenesis35. Following 
vasculogenesis, the majority of the blood vessels are formed by angiogenesis35.  
Angiogenesis involves the following fundamental steps: the basement membrane of the 
existing blood vessel is broken down and the extracellular matrix is degraded33,36. Then, 
endothelial cells migrate into the interstitial space, towards the angiogenic stimuli, 
facilitated by proteases as well as cell adhesion molecules36. Finally, endothelial cells 
proliferate and form the new capillary lumen followed by functional maturation via 
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recruitment of other mural cells such as pericytes33,36,37. Blood vessels provide nutrients 
and oxygen to all tissues as well as facilitate the removal of waste products33,38. In 
addition, blood vessels deliver immune cells, macrophages and even humoral factors to 
tissues38. 
In the ovary, a cyclic reproductive process drives ovarian vascular development36,37. 
Physiological angiogenesis takes place during folliculogenesis, ovulation and luteal 
development37. The outer cortex of the ovary contains a number of ovarian follicles in 
different stages of growth before their maturity and release into the fallopian tube39,40. 
Ovarian follicles contain a single oocyte enclosed by a basal lamina, further surrounded 
by layers of theca cells, which are critical for ovulation and only appear in the early 
secondary stage of ovarian follicle development41. Angiogenesis occurs in the theca layer 
and is essential in the transition of the primary ovarian follicle into the vascular 
secondary follicle36,37. The capillary network does not traverse the basement membrane 
of the granulosa layer. However, follicular growth is dependent on gonadotrophins 
secreted by the theca layer of the ovarian follicle, which stimulates ovulation, causing the 
basement membrane to collapse and allow the blood vessels to penetrate the granulosa 
layer36.  
Angiogenesis also plays a critical role in cancer progression and is one of the vital 
alterations driving malignant tumour growth42. Tumour cells release numerous growth 
factors to mediate dysregulated angiogenesis35. This dysregulation involves both 
excessive vascular expansion and maintenance of a chaotic and immature vascular 
network. Tannock et al. (1968) found that the closer the capillary, the more likely the 
tumour cell will undergo mitosis33,43. Without angiogenesis, solid tumours are unable to 
grow beyond 2 mm3 44. The induction of tumour angiogenesis that results in leaky and 
immature vasculature promotes alteration of perivascular cells, greater permeability and 
the inability to remodel the newly formed vessels35,45. Moreover, tumour cells utilize neo-
vessels to metastasize to distant sites in the body33.  
It has been reported that after menopause or oophorectomy, the decrease in estrogen 
levels leads to elevated gonadotropin hormone levels, which promote tumour growth in 
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vivo by inducing angiogenesis46. Given that the ovarian medulla consists of loose 
connective tissue, vasculature and nerves39, these blood vessels are readily accessible and 
in close proximity to the primary ovarian or fallopian tube and contribute to early 
tumorigenesis. 
1.5 Angiogenesis signaling pathways and involvement in 
ovarian cancer 
Once the tumour reaches a certain size, the tumour microenvironment becomes hypoxic 
and induces the angiogenic switch35,47. The angiogenic switch results from an imbalance 
between pro- and anti-angiogenic factors, facilitating vascular expansion33,47. Various 
growth factors are involved in tumour angiogenesis. Perhaps, the most studied is vascular 
endothelial growth factor (VEGF). VEGF was identified as an endothelial cell-specific 
mitogen that exhibited the capacity to induce physiological and pathological 
angiogenesis48,49. This VEGF is now known as VEGFA and is a member of a large 
family that includes VEGFB, VEGFC, VEGFD and placental growth factor (PGF). These 
VEGF family members differ in expression patterns, cell surface receptor specificity, and 
biological functions50. Increased microvessel density and VEGF expression has been 
shown to correlate with poor prognosis in ovarian cancer34. Signaling by VEGF in 
tumour cells is mediated by cell surface VEGF receptor tyrosine kinases and neuropilins 
(NRPs)51. The classical VEGF receptors include VEGFR1 (also known as FLT1), 
VEGFR2 (also known as FLK1 or KDR) and VEGFR352. Although, most VEGFRs are 
expressed by endothelial cells and numerous tumour cell types53, VEGFR2 is considered 
the predominant receptor that mediates VEGF signaling and drives VEGF-mediated 
angiogenesis52. Engagement of VEGFR2 by VEGF initiates a tyrosine kinase signaling 
cascade that causes endothelial cell proliferation, migration and tubule formation by 
production of other pro- and anti-angiogenic factors33,37,54. Intracellular mediators 
downstream of VEGF-VEGFR include the phosphoinositide 3-kinase (PI3K) pathway, 
which is required for vascular permeability33. Subsequently, protein kinase B (AKT) is 
activated; AKT is responsible for protein synthesis and cell growth via phosphorylation 
of mammalian target of rapamycin (mTOR) signaling pathway33,55. The PI3K/AKT 
pathway also modulates the expression of other angiogenic factors such as nitric oxide, 
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and angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2)56. Ang1 ensures stable and mature 
blood vessels by securing endothelial cell-cell junctions, decreasing endothelial sprouting 
and enhancing pericyte coverage17. Ang1 is also widely expressed in normal adult 
tissue17. Ang2, on the other hand, functions as an endothelial-derived negative regulator 
of Ang1 signaling during angiogenesis, thereby controlling the responsiveness of 
vascular endothelial cells to exogenous stimuli57.  
Unlike VEGF, family member PGF is dispensable for development but exhibits non-
redundant roles in tissue ischemia, malignancy, and multiple other diseases. In addition, 
PGF binds primarily to VEGFR1, unlike VEGFA which binds to both VEGFR1 and 
VEGFR258. The pro-angiogenic activity of PGF is mediated by direct effects on 
endothelial and perivascular cells, resulting in enhanced vascular cell proliferation, 
migration, and survival59-62. Since PGF primarily binds VEGFR1, it was initially thought 
that PGF limits and displaces VEGFA from VEGFR1, thereby liberating VEGFA to 
activate VEGFR263. This suggests that endothelial cells or cancer cells can enhance or 
modulate responsiveness to VEGFA by releasing PGF64. PGF may also indirectly 
contribute to tumour angiogenesis through upregulation of factors such as VEGFA, 
fibroblast growth factor-2 (FGF2), platelet-derived growth factor-B (PDGFB), and matrix 
metalloproteinases (MMPs)65,66. 
Levels of angiogenic factors VEGF, FGF, PDGF, tumor necrosis factor-alpha (TNF-ɑ), 
ephrins, angiopoietins and interleukins such as IL6 and IL8 have been shown to be 
increased in ovarian cancer specimens compared to normal ovarian tissue34,45. 
Furthermore, many of these angiogenic factors regulate the expression of other 
angiogenic factors. For example, TNF-ɑ upregulates different growth factors, cytokines 
and chemokines, which ultimately contribute to a pro-angiogenic microenvironment67. 
Moreover in HGSOCs, VEGF increases vascular permeability of peritoneal blood 
vessels; the leaky vessels consequently lead to malignant ascites45. VEGF also increases 
expression of MMPs, enhancing tumour cell invasion45. 
Counteracting pro-angiogenic factors are the anti-angiogenic factors such as 
thrombospondins (TSPs), angiostatin, and endostatin33. TSP-1 for example, supresses 
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angiogenesis in two ways: 1) by suppressing migration and inducing apoptosis of 
endothelial cells or 2) by inhibiting co-receptors shared with pro-angiogenic factors on 
the endothelial cell surface68. However, the receptor engaged by TSP is of paramount 
importance in mediating any anti-angiogenic effects. For example, CD36 is expressed by 
endothelial cells as a receptor for TSP-1 and is necessary for the anti-angiogenic 
activity69. However, binding of TSP to alpha-3/beta-1, alpha-4/beta-1, and alpha-9/beta-1 
integrin results in pro-angiogenic effects70-72. In addition, oncogenes such as c-jun and 
loss of tumour suppressor genes such as TP53 have been shown to regulate TSP 
expression, thus disturbing the angiogenic balance in favour of angiogenesis68. Although 
several TP53 mutations result in gain-of-function in HGSOC, whether TSP is altered and 
which receptors may be engaged is not fully known20,73.  
1.6 Anti-angiogenic therapies in ovarian cancer 
The inhibition of angiogenic factors involved in ovarian cancer is emerging as a 
therapeutic strategy74,75. These therapies are being explored in conjunction with standard 
chemotherapy56,76-78. Monoclonal antibodies, endogenous peptide inhibitors, small 
molecule drugs and microRNAs have been developed over the past ten years to 
counteract angiogenesis78. Bevacizumab (Avastin), a monoclonal anti-VEGF antibody, 
was one of the first US Food and Drug Administration (FDA) approved anti-angiogenic 
drugs17,77. Another example is VEGF Trap, or Aflibercept, which is a fusion protein with 
affinity to VEGFA, VEGFB and PGF17. VEGF Trap prevents binding of VEGF ligands 
to cell-surface receptors79. In a phase 2 clinical trial, Avastin was administered to 
relapsed platinum-resistant ovarian cancer patients as a monotherapy, and showed 
improvement in median progression-free survival (PFS) of less than 5 months and overall 
survival by 17 months17. These monotherapies were also accompanied by adverse side 
effects such as hypertension and gastrointestinal perforations among others17. 
Combination of chemotherapy and anti-angiogenic therapies has also been tested in 
Phase 3 trials with varying treatment regimens. Although improving PFS by a few 
months, overall survival by the combination therapy did not change17. Other novel 
developments to combat pathological angiogenesis have included small molecule 
vascular disrupting agents (VDAs) to target existing blood vessels as opposed to targeting 
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factors that play a role in neovascularization79,80. VDAs target vasculature by binding to 
endothelial cell tubulin. Combretastatin A4-phosphate (CA4P), for example, targets 
endothelial cells without complete perivascular cell coverage. CA4P has shown improved 
PFS in combination with Avastin in ovarian cancer79. A phase 2/3 clinical trial is 
currently underway to assess the therapeutic effect of a combination of VDAs, 
chemotherapy, and anti-angiogenic agents79. Although these are promising developments, 
the efficiency and dose-limiting toxicities accompanying some of the treatment regimens 
are lingering concerns. In addition, resistance to anti-angiogenic agents involving VEGF 
are poorly understood80. Therefore, it is imperative to explore alterative pathways that 
may be involved in ovarian cancer angiogenesis to develop new targets and increase the 
efficiency of current ones. 
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Chapter 2  
2 PURPOSE AND OBJECTIVES OF THESIS 
2.1 Purpose of thesis 
Resistance to platinum-based chemotherapy is a major clinical challenge in ovarian 
cancer treatment and the reasons behind chemotherapy failure is poorly understood28,81. 
Anti-angiogenic therapies targeting VEGFA and similar angiogenic genes have shown to 
disrupt tumour angiogenesis81. Pilot studies performed in our laboratory by previous 
members showed unexpected vascular proliferation in ovarian serous carcinoma 
following carboplatin treatment (unpublished data). Specifically, histological analyses of 
paraffin-embedded ovarian serous adenocarcinoma specimens from nine pre-
chemotherapy biopsies and patient-matched post-chemotherapy resections showed 
microvascular proliferation in carboplatin-treated specimens. Moreover, early 
morphological observations have shown viable tumour cells near vascular proliferation 
following carboplatin treatment (unpublished data). In addition, a number of cytokines, 
matrix proteins and growth factor exhibited increased levels in post-chemotherapy 
specimens, such as pro-angiogenic Ang1 (unpublished data, Figure 2.1.1 – Dr. Iram 
Siddiqui and Sandra Mekhaiel, 2014). Little is known about the effect of chemotherapy 
on ovarian cancer tumour vasculature, and vascular proliferation following carboplatin 
therapy may point to an important mechanism by which ovarian cancer may escape the 
therapeutic effect of carboplatin. Interestingly, Wild et al. (2004) have shown that 
carboplatin significantly increased the expression of VEGFA in endothelial cells, and 
when VEGFA was inhibited, endothelial cell sensitivity to carboplatin significantly 
increased81. The investigators also showed that carboplatin treatment did not alter 
VEGFA expression in tumour cells. Therefore, it is imperative to understand the response 
of ovarian cancer and endothelial cells to carboplatin. These studies may lead to a better 
understanding of the tumour microenvironment post-carboplatin exposure, to the 
development of new therapeutic targets for ovarian cancer and/or rationalize combination 
treatment regimens. 
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2.2 Hypothesis and objectives 
My studies explore the mechanisms underlying the effects of carboplatin on ovarian 
cancer angiogenesis. I hypothesize that carboplatin induces angiogenic factors in ovarian 
cancer cells leading to microvascular endothelial cell survival. 
My specific aims are as follows:  
1: Identify alteration of angiogenic genes in ovarian cancer cells following 
carboplatin exposure. 
Figure 2.1.1 Angiopoietin 1 staining in patient pre-chemotherapy (Pre-CT) 
treatment biopsy versus patient-matched post-chemotherapy (Post-CT) treatment 
surgical resection. Representative immunofluorescence (IF) staining of angiopoietin 1 
(green) in ovarian serous adenocarcinoma specimens [pre-CT = biopsy specimens prior 
to initiating chemotherapy, post-CT = specimens resected following chemotherapy; 
nuclei stained with DAPI (blue)]. Right panel shows quantification of fluorescence 
intensity by Image J (https://imagej.nih.gov/ij/). Staining intensity is presented in 
arbitrary units (AU) [Student’s t-test was used for data analysis].   
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2: Investigate the functional significance of carboplatin-induced angiogenic genes 
using vascular endothelial cells. 
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Chapter 3  
3 MATERIALS AND METHODS 
3.1 Ovarian cancer and vascular endothelial cells 
HGSOCs make up approximately 80% of ovarian cancer diagnoses, are clinically 
aggressive and are responsible for the most gynecological cancer-related deaths in 
Canadian women29. Therefore, I elected to use two ovarian cancer cell lines of this 
histological subtype for my studies. Ovarian cancer cell line COV362 was obtained from 
Sigma-Aldrich (Oakville, ON, Canada). COV362 was originally identified as epithelial-
endometrioid carcinoma82, but is now considered a top-ranking HGSOC-like line14. This 
confusion is not surprising as some high-grade endometrioid adenocarcinomas are 
difficult to distinguish from HGSOC molecularly83. Some high grade endometrioid 
adenocarcinomas also have TP53 mutations as well as a high correlation of CNA with 
HGSOCs84. In addition to COV362, I used an established ovarian serous carcinoma cell 
line, COV318 (Sigma-Aldrich). Human dermal microvascular endothelial cells 
(HDMECs; Lonza Inc.) were used for functional tests and to identify autocrine 
angiogenic factors. 
3.2 Cell culture 
COV362 and COV318 ovarian cancer cells were cultured on uncoated plastic plates in 
Dulbecco’s Modified Eagle Medium (DMEM; Life Technologies) supplemented with 
10% Fetal Bovine Serum (FBS; Life Technologies) and 1x antibiotic antimycotic media 
(penicillin, streptomycin, and amphotericin, PSF; Mediatech Inc.). HDMECs were 
cultured on uncoated plastic plates in complete Endothelial Basal Media-2 (EBM-2; 
Lonza Inc.) supplemented with 20% FBS, 1x PSF, and EGM-2 SingleQuots (Lonza Inc.) 
containing VEGF, insulin-like growth factor-1, human epidermal growth factor, human 
FGF, ascorbic acid, heparin, hydrocortisone and gentamicin/amphotericin B. Besides 
different culture media, all other conditions were identical. 
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3.3 Cell viability assays  
To establish the effect of carboplatin exposure, COV362, COV318 and HDMECs were 
seeded at 10,000 cells/cm2 in respective growth media and allowed to attach overnight. 
The next day, media was changed to fresh growth media containing varying 
concentrations of carboplatin (Sigma; molecular weight 371.3 g/mol) including 0 
(control), 1, 10, 25, and 50 µg/mL (3 µM, 79 µM, 67 µM, and 135 µM, respectively). 
Carboplatin challenge was carried out for 72 hours with three experimental replicates per 
condition. This concentration range was based on a study by Wild et al. (2004) where 
investigators exposed endothelial cells and human ovarian carcinoma MA148 cells to 
carboplatin81. In that study, endothelial cells showed 50% viability upon exposure to 50-
70 µg/mL (135 µM – 190 µM) carboplatin as assessed by MTT assay. In my study, 
viable cell counts and live/dead percentages were measured using Scepter Handheld 
Automated Cell Counter (Millipore) and Trypan blue exclusion test by Countess II (Life 
Technologies), respectively. Scepter cell counter uses the Coulter principle of impedance-
based particle detection to reliably and accurately count cells. The concentration which 
showed significant decrease in cell viability across all cell types relative to control was 
used for subsequent experiments. 
3.4 RNA isolation and qRT-PCR 
Identification of angiogenic factors was performed by profiling mRNA levels of known 
angiogenesis factors in cells. Cells were seeded at 10,000 cells/cm2 and cultured 
overnight before exposing to 50 µg/mL (135 µM) carboplatin for 72 hours. RNA was 
isolated using RNeasy Micro Plus Kit (Qiagen). Amount of RNA yield was determined 
by Qubit RNA Broad Range Assay in a Qubit Fluorometer (Life Technologies). Then, 
cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad Laboratories). Gene 
expression analysis was performed using RT2 Human Angiogenesis PCR arrays (PAHS-
072ZD; Qiagen) (Plate 1) in Bio-Rad CFX Connect. All reactions were performed using 
RT² SYBR® Green qPCR Mastermix (Qiagen) and nuclease-free H2O. Target mRNA 
levels were analyzed by CFX Manager Software (Bio-Rad Laboratories), and by using 
the ΔΔCT method. Normalization to five housekeeping genes was carried out. These 
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housekeeping genes included β-actin (ACTB), β2-microglobulin (B2M), glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), hypoxanthine-guanine phosphoribosyl transferase 
(HPRT1) and ribosomal protein lateral stalk subunit P0 (RPLP0). A full list of all 
angiogenic genes and appropriate PCR controls on Plate 1 can be found in Appendix 1. 
 
 
Plate 1 RT2 Human Angiogenesis PCR Array. The plate contained a selection of 84 
different angiogenic genes, as well as housekeeping genes and PCR controls. 
 
All reactions were performed for 50 cycles with the following temperature profiles: 95οC 
for 10 minutes (initiation), and 50 cycles of 95οC for 15 seconds (denaturation), 60οC for 
1 minute (annealing, extension, and measurement). All PCR studies were coupled to 
melting curve analysis with the following profile: 95οC for 10 seconds, followed by 65οC 
for 5 seconds, and 95οC for 5 seconds. 
3.5 Carboplatin-condition media 
To prepare condition media, ovarian cancer cells were seeded at 10,000 cells/cm2 
overnight. Cells were then exposed to 0 μg/mL (control) and 50 μg/mL (135 µM) 
carboplatin for 72 hours. Following exposure, viable cell number was measured in 
replicates using Sceptor cell counter. This cell number was used to normalize condition 
media as described below. Subsequently, media was replaced with DMEM/0.5% FBS 
media and cells were incubated for 24 or 48 hours. DMEM/0.5% FBS was selected 
because it adequately sustains viable cells without complete starvation, this was 
determined empirically in our laboratory. After the appropriate time point, the media was 
collected and passed through 2 µm filters. Viable cell number was measured at time of 
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media collection. Condition media was normalized relative to the number of cells 
measured after 72 hours of initial exposure to carboplatin (Figure 3.5.1). In addition, 
carboplatin-containing media was added to culture dishes without any cells. This group 
was designed as negative control to test for any potential effects of residual carboplatin 
which may be transferred while preparing condition media. 
 
3.6 Endothelial cell survival assay 
To assess the effect of potential angiogenic factors released by ovarian cancer cells 
following exposure to carboplatin, I utilized an endothelial cell survival assay. HDMECs 
were seeded at 5,000 cell/cm2 in EBM2 media supplemented with 20% FBS and 1x PSF. 
After overnight culture, cells were washed and exposed to condition media from 
COV318 and COV362 (Methods and Materials 3.5; Figure 3.5.1). HDMECs were also 
Figure 3.5.1 Preparation of condition media. Cells were plated at 10,000 cells/cm2 and 
exposed to 50 μg/mL (135 µM) carboplatin for 72 hours. Media was replaced with a low 
serum-containing media (DMEM/0.5% FBS) for 24 or 48 hours. Viable cell count was 
measured at 72 hours following carboplatin exposure, and following low serum media 
collection. The condition media was filtered, collected and normalized to the number of 
cells from the 72-hour count. 
  
17 
 
cultured in fresh EBM2/20% FBS as positive control. Following 48 hours of incubation, 
viable cell number was measured and data was normalized to DMEM/0.5% FBS control. 
Endothelial cell survival assay was also performed with recombinant proteins of interest. 
PGF and IL1B were significantly upregulated after carboplatin exposure in my qRT-PCR 
experiments across all three cell types used in this study: HDMEC, COV362 and 
COV318 (Results 4.3). To that end, I investigated the functional significance of PGF as 
well as its potential interaction with VEGFA, the main driver of angiogenesis, on 
endothelial cell survival by adding recombinant human proteins to HDMEC cultures. 
HDMECs were plated and allowed to attach. Cells were then exposed to DMEM/0.5% 
FBS media containing 10 ng/mL recombinant human VEGFA (rVEGFA, R & D 
Systems) and/or 10 ng/mL recombinant human PGF (rPGF, PeproTech Inc.). Cells were 
incubated for 48 hours and viable cell number was measured and normalized to 
DMEM/0.5% FBS control. 
3.7 Immunocytochemistry 
Ovarian cancer cells COV318 and COV362 were seeded at 10,000 cells/cm2 on uncoated 
Nunc™ Lab-Tek™ II 8-chambered slides (Thermo Fisher). Cells were then exposed to 
50 μg/mL (135 µM) carboplatin for 72 hours. Some cells were treated with 500 nM or 1 
μM Wingless-type MMTV integration site family member (Wnt) agonist. Initially, cells 
were probed for PGF by labeling cells with primary PGF antibody (based on results, see 
section 4.3). However, PFG staining was not robust and did not yield meaningful data. As 
a positive control for the staining studies, I used primary rabbit anti-β-catenin antibody 
(ab6302, Abcam). Briefly, cells were fixed with methanol and incubated with anti-β-
catenin antibody for 1 hour at room temperature. PBS containing 1% bovine serum album 
was used as diluent. Subsequently, all slides were incubated with the appropriate 
fluorophore-conjugated secondary antibody for 1 hour at room temperature. Slides were 
counterstained using ProLong® Diamond Antifade Mountant containing 4, 6’ diamidino-
2-phenylindole (DAPI) (Life Technologies). To test for non-specific secondary antibody 
staining, secondary antibody incubation without primary antibody incubation was used as 
negative control. Images were obtained using Olympus BX-51 fluorescence microscope 
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(Olympus Canada Inc.) equipped with SPOT digital camera. Images were processed by 
SPOT Imaging Software (SPOT Imaging Solutions). 
3.8 Effect of Wnt pathway activation on PGF and IL1B 
expression 
I then wanted to investigate whether the angiogenic factors of interest (PGF and IL1B) 
induced by carboplatin may potentially be induced by the Wnt/β-catenin pathway using 
Wnt agonist (Material and Methods 3.7). I cultured ovarian cancer cells and exposed 
COV362 and COV318 to 500 nM, 1 μM and 2 μM Wnt agonist (Millipore Calbiochem; 
CAS 853220-52-7) for 48 hours. RNA was isolated and cDNA was synthesized as 
previously described (Material and Methods 3.4). Gene expression was assessed by 
qRT-PCR, using PGF and IL1B primers (Qiagen; Table 3.4.1) and RT2 SYBR Green 
Mastermix. Data was analyzed by CFX Manager Software by the ΔΔCT method and 
target gene mRNA data was normalized to β-actin. 
Table 3.8.1 List of primers used. 
Gene Source (Catalogue ID) 
B-actin Qiagen (QT01680476) 
PGF Qiagen (QT00030688) 
IL1B Qiagen (QT00021385) 
 
3.9 Statistical analysis 
Statistical analysis was performed using student’s t-test or ANOVA where applicable. 
Quantitative PCR data was analyzed by CFX Manager Software. Data are expressed as ± 
SD. P values less than 0.05 were considered statistically significant. 
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Chapter 4  
4 RESULTS 
4.1 Effect of carboplatin on ovarian cancer and endothelial 
cells 
My first aim was to determine a carboplatin concentration that significantly decreases 
viability of ovarian cancer cells. This was essential to identify potential angiogenic factor 
production in response to carboplatin exposure. Based on a recent study81, I anticipated 
that carboplatin may reduce viability at 50 µg/mL (135 µM), at least in endothelial cells. 
Wild et al. (2004) also showed that MA148 ovarian cancer cells exhibit significantly 
reduced viability at 0.7 μg/mL (2 µM) 81. However, these MA148 cells are less 
characterized as compared to other available cell lines and are simply described in the 
literature as epithelial ovarian carcinoma85. Therefore, I exposed ovarian cancer cells and 
endothelial cells to carboplatin at concentrations of 0, 10, 25, and 50 μg/mL (3 µM, 79 
µM, 67 µM, and 135 µM, respectively) for 72 hours. My results show that 50 μg/mL 
carboplatin significantly decreases viability of both ovarian cancer cell lines as well as 
that of vascular endothelial cells compared to respective control media (Figures 4.1.1 A, 
B and C). Contrary to the previous report81, my results indicate that HDMECs are more 
sensitive to carboplatin than ovarian cancer cells. HDMECs exhibited significantly lower 
viability at 10 µg/mL (79 µM), whereas viability of ovarian cancer cells was not affected 
by carboplatin at 10 µg/mL. Approximately 50 percent reduction in viable cell counts 
were noted in ovarian cancer cells following carboplatin exposure at 25-50 µg/mL (67 
µM - 135 µM). Based on these results, 50 μg/mL carboplatin was selected for subsequent 
studies as it produced significant reduction in viability in all three cell types. 
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Figure 4.1.1 Effect of carboplatin on ovarian cancer cells and endothelial cells. Cells 
were exposed to 0 μg/mL, 10 μg/mL, 25 μg/mL or 50 μg/mL (3 µM, 79 µM, 67 µM, and 
135 µM respectively) carboplatin for 72 hours. Total cell count was measured for 
HDMEC (endothelial cells- yellow A), COV362 (endometrioid ovarian cancer cells- 
blue B) and COV318 (serous ovarian cancer cells- green C). n=3. Data expressed as 
mean ± SD; *p < 0.05.  
A B 
C 
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4.2 Carboplatin induced cell death 
As viability is a sum of both positive and negative growth signals, I examined whether 
carboplatin was inducing cell death in this experimental platform. To measure cell death, 
I utilized the trypan blue exclusion test86. Since the focus of my studies was to identify 
angiogenic factors produced in response to carboplatin and not necessarily the 
mechanism of cell death, trypan blue dye test was sufficient for this purpose. HDMECs, 
COV362 and COV318 cells were exposed to 50 μg/mL carboplatin for 72 hours and then 
stained with trypan blue. Live and dead percentage was measured using Countess II 
automated cell counter. Results show approximately 70% cell death in HDMECs 
following carboplatin exposure (Figure 4.2.1A). A similar level was obtained in 
COV362 (Figure 4.2.1B) and COV318 cells (Figure 4.2.1C). Therefore, carboplatin 
reduces viability by inducing cell death. 
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Figure 4.2.1 Total Live/Dead percentage of endothelial cells and ovarian cancer cells 
post-carboplatin exposure. Cells were exposed to 50 μg/mL (135 µM) carboplatin for 
72 hours and live/dead percentage was measured by trypan blue exclusion test. Results 
shown represent average of at least 2 experimental replicates. 
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4.3 Effect of carboplatin on angiogenic gene expression 
profile 
My next objective was to identify potential angiogenic factors which may be induced in 
ovarian cancer cells following carboplatin exposure. To achieve this, HDMECs, COV362 
and COV318 cells were exposed to 50 μg/mL carboplatin for 72 hours. RNA was 
isolated and qRT-PCR was performed to profile angiogenic factors. RT2 PCR array 
comprised of various growth factors, cytokines, extracellular matrix proteins, intracellular 
mediators and cell surface protein genes involved in angiogenesis (Plate 1, Appendix 1). 
There were several genes that showed greater than two-fold increase after carboplatin 
exposure in HDMECs (Figure 4.3.1), COV362 (Figure 4.3.2) and COV318 cells 
(Figure 4.3.3).  
It is interesting to note that HDMECs also showed increased angiogenic factor expression 
possibly indicating autocrine regulation of neovascularization. Levels of angiopoietin-
like 4 (ANGPTL4), interferon alpha 1 (IFNA1), interleukin 1 beta (IL1B), PGF, 
plasminogen activator, urokinase (PLAU), plasminogen activator inhibitor type-1 
(SERPINE1), transforming growth factor beta receptor 1 (TGFBR1) and VEGFA were all 
increased in HDMECs (Figure 4.3.1). Of these numerous factors, only VEGFA has been 
shown to be induced by carboplatin previously81. 
In comparison to HDMECs, COV362 cells showed significant increases in ANGPTL4, 
Chemokine (C-X-C motif) ligand 5 (CXCL5), Ephrin-A1 (EFNA1), coagulation factor 
(F3), fibroblast growth factor 1 (FGF1), fibroblast growth factor receptor 3 (FGFR3), 
IL1B, interleukin-6 (IL6), leukocyte cell derived chemotaxin 1 (LECT1), matrix 
metallopeptidase 9 (MMP9), NOTCH4, PGF, sphingosine-1-phosphate (S1PR1), 
sphingosine kinase 1 (SPHK1) and transforming growth factor alpha (TGFA) (Figure 
4.3.2).  
COV318 were included to strengthen the results. My data showed significant increase in 
angiogenin (ANG), collagen, type IV, alpha 3 (COL4A3), EFNA1, F3, FGF1, FGF2, 
hepatocyte growth factor (HGF), IL1B, IL6, midkine (MDK), NOTCH4, PDGFA, PGF, 
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Figure 4.3.1 Angiogenic gene expression profile of HDMEC in response to 
carboplatin. Gene expression of various growth factors with significantly increased 
(greater than 2-fold, p < 0.05) levels post 72-hour 50 μg/mL (135 µM) carboplatin 
exposure relative to control (0 μg/mL). Control represented by value line 1 (purple). 
Relative expression normalized to ACTB, B2M, GAPDH, HPRT1 and RPL0P. Data is 
derived from at least 3 experimental replicates and expressed as mean + SD. 
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S1PR1, SERPINE1, SPHK1, transforming growth factor beta 1 (TGFB1) and 
thrombospondin (THBS1) (Figure 4.3.3). 
Comparison of all three cell types showed that PGF and IL1B were induced by 
carboplatin in all cells used in my studies (Table 4.2.1). 
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Figure 4.3.2 Angiogenic gene expression profile for COV362 in response to 
carboplatin. Gene expression of various growth factors with significantly increased 
(greater than 2-fold, p < 0.05) levels post 72-hour 50 μg/mL (135 µM) carboplatin 
exposure relative to control (0 μg/mL). Control represented by value line 1 (purple). 
Relative expression normalized to ACTB, B2M, GAPDH, HPRT1 and RPL0P. Data is 
derived from at least 3 experimental replicates and expressed as mean + SD. 
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Figure 4.3.3 Angiogenic gene expression profile for COV318 in response to 
carboplatin. Gene expression of various growth factors with significantly increased 
(greater than 2-fold, p < 0.05) levels post 72-hour 50 μg/mL (135 µM) carboplatin 
exposure relative to control (0 μg/mL). Control represented by value line 1 (purple). 
Relative expression normalized to ACTB, B2M, GAPDH, HPRT1 and RPL0P. Data is 
derived from at least 3 experimental replicates and expressed as mean + SD. 
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Table 4.3.1 Common target mRNA expression-fold in HDMEC, COV362 and 
COV318. 
 Relative normalized expression  
Gene HDMEC COV362 COV318 
IL1B 4.9 10.7 6.4 
PGF 21.1 47.4 3.2 
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4.4 The effect of ovarian cancer cell condition media on 
endothelial cells 
My results show that a host of angiogenic factors are induced by carboplatin in ovarian 
cancer cells and endothelial cells. My next objective was to determine the functional 
significance of this induction. I subjected endothelial cells to condition media prepared 
from ovarian cancer cells exposed to carboplatin and assessed viability. This is a 
modified cell survival assay and employs low serum levels to determine whether 
condition media is able to sustain or enhance cell viability. Endothelial cells were plated 
and allowed to attach. Cells were then exposed to ovarian cancer condition media.  
Negative control condition media was used to determine whether any residual carboplatin 
from media transfers and washes may negatively affect the experimental readout. My 
results show that negative control media does not significantly change viable cell counts 
(data not shown). HDMECs also showed increased viability counts in EBM2/20% FBS 
media as expected (data not shown). Incubation of endothelial cells with condition media 
produced interesting results. First, I tested condition media collected over a 24-hour 
period following carboplatin exposure. Condition media prepared from COV362 cells 
with 50 µg/mL carboplatin increased cell viability as compared to control media (no 
carboplatin) (Figure 4.4.1). This increase was also evident when comparing the condition 
media to fresh DMEM/0.5% FBS control. However, condition media prepared from 
COV318 cells did not show any significant alterations (Figure 4.4.1).  
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Figure 4.4.1 HDMEC response to 24-hour condition media.  HDMECs were exposed 
to condition media prepared from COV362 or COV318 cells for 48 hours. N=2 
(endothelial cell preparation); n=6 (experimental replicates). Data expressed as mean ± 
SD. NS = not significant, *p < 0.05. 
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It is possible that 24-hour collection period for COV318 cell condition media is not 
sufficient to produce any effects. In support of this notion, my studies show that COV318 
increase PGF by approximately 3-fold as compared to 40-fold induction in COV362 cells 
(Table 4.3.1). The same pattern is seen with IL1B. Therefore, I increased the collection 
period to 48 hours. Endothelial cells exposed to COV362 condition media did not 
indicate significant increase in viable cell number after carboplatin exposure versus 
control (Figure 4.4.2). However, compared to DMEM/0.5% FBS control, viability was 
significantly increased (Figure 4.4.2). In addition, HDMEC viability was significantly 
increased when exposed to COV318 condition media with carboplatin (Figure 4.4.2).  
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Figure 4.4.2 HDMEC response to 48-hour condition media. HDMECs were exposed 
to condition media prepared from COV362 or COV318 cells for 48 hours. N=1 
(endothelial cell preparation); n=6 (experimental replicates). Data expressed as mean ± 
SD. NS = not significant, *p < 0.05. 
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4.5 Recombinant PGF induces endothelial cell growth 
As all three cell types showed increased expression of PGF, it represented an interesting 
target as it may directly affect endothelial cells, as well as indirectly by eliciting other 
angiogenic factors76. PGF is postulated to stimulate angiogenesis by binding to VEGFR1 
and stimulating downstream signals87. Binding to VEGFR1 by PGF also displaces 
VEGFA which is then able to bind VEGFR2 to initiate angiogenic effects87. Moreover, 
Carmeliet et al. (2001) showed that the addition of PGF or VEGF alone resulted in 
minimal outgrowth in aortic ring capillary growth assay. However, PGF and VEGF 
together strongly stimulated capillary outgrowth87.  
To elucidate the roles of PGF and VEGF and investigate possible synergy, I exposed 
HDMECs to recombinant human PGF (rPGF) and recombinant human VEGFA 
(rVEGFA) for 48 hours. There was a significant increase in viable cell number when 
HDMECs were treated with 10 ng/mL rPGF, rVEGFA, or the combination of the two 
factors compared to the control DMEM/0.5% FBS (Figure 4.5.1). rVEGFA was more 
potent in increasing cell viability compared to rPGF (Figure 4.5.1). However, there was 
no significant difference between HDMECs exposed to rVEGFA versus combination 
exposure of rPGF and rVEGFA. This suggests two important biological phenomena. 
First, rPGF alone is able to increase HDMEC growth and second, that rPGF does not 
enhance the effect of rVEGFA. 
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Figure 4.5.1 HDMEC viability in response to recombinant PGF and VEGFA. 
HDMECs were exposed to 10 ng/mL recombinant PGF and/or VEGFA for 48 hours. 
N=2 (endothelial cell preparations); n=6 (experimental replicates). Data expressed as 
mean + SD. NS = not significant, *p < 0.05. 
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4.6 Nuclear β-catenin translocation following carboplatin 
exposure 
I performed immunofluorescence (IF) staining to confirm PGF induction in ovarian 
cancer cells after carboplatin exposure as seen in Figure 4.3.2 (COV362) and Figure 
4.3.3 (COV318). β-catenin was initially included as a positive control. β-catenin is found 
in a complex with epithelial (E)-cadherin at cell-cell junctions in epithelial cells. IF 
staining was unable to provide a robust signal from PGF (data not shown). This is not 
fully unexpected as these are secreted growth factors. However, interesting and 
unexpected results were obtained when ovarian cancer cells were stained for β-catenin. 
Following carboplatin exposure, decreased membrane localization of β-catenin and 
increased nuclear β-catenin was noted in COV362 and COV318 cells (Figure 4.6.1 and 
Figure 4.6.2). Nuclear β-catenin has been reported to be implicated in mediating the 
epithelial-mesenchymal transition (EMT) in a variety of human cancers. During this 
process, epithelial cells lose expression of proteins like E-cadherin, and β-catenin 
translocates to the nucleus to transcribe β-catenin-responsive genes. Interestingly, 
elevated β-catenin activity was recently shown to contribute to carboplatin resistance in 
A2780cp ovarian cancer cells88. 
To confirm whether nuclear β-catenin following carboplatin exposure is analogous to 
Wnt pathway activation, I treated ovarian cancer cells with a Wnt agonist and localized 
β-catenin. My results show that Wnt agonist reduces membrane-associated β-catenin after 
48 hours relative to control (unexposed to Wnt agonist) in both COV362 cells and 
COV318 cells (Figure 4.7.1). These results may indicate canonical Wnt pathway 
activation89.  
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Figure 4.6.1 β-catenin localization in COV318 cells.  Immunofluorescence (IF) 
staining of β-catenin (green) in control and carboplatin-challenged cells. Carboplatin 
exposure was carried out for 72 hours. Cells were counterstained with DAPI nuclear stain 
(blue). 
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Figure 4.6.2 β-catenin localization in COV362 cells. Immunofluorescence (IF) staining 
of β-catenin (green) in control and carboplatin-challenged cells. Carboplatin exposure 
was carried out for 72 hours. Cells were counterstained with DAPI nuclear stain (blue). 
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Figure 4.6.3 β-catenin localization after Wnt agonist treatment in COV318 and 
COV362 cells. Immunofluorescence (IF) staining of β-catenin (green) in control and Wnt 
agonist-treated cells. Cells were counterstained with DAPI nuclear stain (blue). 
  
38 
 
4.7 IL1B and PGF mRNA expression are upregulated after 
Wnt pathway activation 
My results pointed to a novel mechanism involving activation of the Wnt pathway by 
which carboplatin may induce angiogenic factors. Therefore, I examined mRNA levels of 
PGF and IL1B following Wnt agonist exposure. I treated ovarian cancer cells to 500 nM, 
1μM or 2 μM Wnt agonist for 48 hours. qPCR results show that IL1B is significantly 
upregulated following treatment of COV362 and COV318 with Wnt agonist (Figure 
4.7.1 and Figure 4.7.2). mRNA levels of PGF were also increased by Wnt agonist in 
COV362 cells (Figure 4.7.1). Interestingly, COV318 cells showed decreasing mRNA 
levels of PGF after treatment with Wnt agonist (Figure 4.8.2). 
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Figure 4.7.1 IL1B and PGF mRNA levels in COV362 cells treated with Wnt agonist. 
COV362 cells were exposed to 500 nM or 1 μM Wnt agonist for 48 hours. PGF and IL1B 
mRNA expression was normalized to β-actin. Results representative of three independent 
experiments. Data expressed as mean ± SD, *p < 0.05. 
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Figure 4.7.2 IL1B and PGF mRNA levels in COV318 cells treated with Wnt agonist. 
COV318 cells were exposed to 500 nM or 1 μM Wnt agonist for 48 hours. PGF and IL1B 
mRNA expression was normalized to β-actin. Results representative of three independent 
experiments. Data expressed as mean ± SD, *p < 0.05. 
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Chapter 5  
5 DISCUSSION 
The salient findings of my study show that carboplatin reduces viability of ovarian cancer 
cells and vascular endothelial cells. Interestingly, this reduced viability was associated 
with induction of a host of angiogenic genes. These factors included PGF and IL1B 
which were induced in the major cellular compartments of the ovarian tumour: tumour 
cells and vessel-lining endothelial cells. Ovarian cancer cell-induced factors increase 
viability of vascular endothelial cells as shown by my condition media studies. The 
results were mimicked by purified recombinant PGF. My studies also suggest that 
carboplatin may induce angiogenic factors including PGF and IL1B through the 
activation of Wnt/β-catenin pathway. I will dissect these key findings and discuss their 
implications below. 
5.1 Ovarian cancer cells and endothelial cells in response 
to carboplatin 
Ovarian cancer cells and endothelial cells showed significant cytotoxic response to 
carboplatin. After carboplatin exposure, percent of dead cells in cultures of HDMEC, 
COV362 and COV318 cells reached 69%, 78% and 59%, respectively (Figure 4.2.1). 
Variability between experimental and biological replicates (different cell preparations) 
may present some limitation in accuracy; but fundamentally, there was a cytotoxic effect 
to carboplatin exposure. Although statistical testing was not performed on data showing 
the percent of live and dead cells because of this inherent variability, the results showing 
dramatically reduced viability provide confidence. My results are contrary to ones 
obtained in a recent and only study of this type81. Wild and colleagues (2004) utilized 
human umbilical vein endothelial cells and MA148 ovarian carcinoma cells and showed 
that cancer cells are almost 100-fold more sensitive to carboplatin as compared to 
endothelial cells. There are potentially two reasons for the different results. First, human 
umbilical vein endothelial cells are typically used as models of large vessels which may 
be quite different in terms of proliferation and angiogenic responses90. Second, MA148 
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ovarian cancer cell line is not fully characterized85. In my study, I examined the effect of 
carboplatin in microvascular endothelial cells as well as two well characterized ovarian 
cancer cell lines. Even though the COV362 cell line was originally annotated as an 
endometrioid ovarian carcinoma, extensive molecular profiling by Domcke et al. (2013) 
has shown that it is one of the top-ranked HGSOC cancer line. Moreover, the COV362 
line is known to be more resistant to platinum-based chemotherapy91; it is therefore 
conceivable that increased angiogenic factors released by these tumour cells upon 
carboplatin treatment may uncover drivers of tumour survival. To bolster my results, I 
also used the COV318 cell line which also matched its original annotation as HGSOC by 
molecular profiling14. Utilizing these two ovarian cancer cells and human microvascular 
endothelial cells, I show that carboplatin reduces the viability consistency to levels 
reaching 50% of controls when carboplatin is used at 25-50 µg/mL (67 µM - 135 µM). It 
is also interesting to note that viability did not differ in any of the cell types at 25 µg/mL 
carboplatin versus 50 µg/mL. Almost half of the cells in culture survived exposure to 
extremely high concentrations of carboplatin and it is possibly these surviving cells 
produce and release angiogenic factors. 
As an alkylating agent, carboplatin causes DNA cross-linkages and disruptions which 
require complex mechanisms of repair28. The DNA mismatch repair (MMR) mechanism 
maintains genomic stability and recognizes DNA alteration caused by carboplatin and 
generates an injury signal that may initiate apoptosis of the cell92. It was reported that 
carboplatin resistance may occur due to the loss of MMR as well as the loss of its 
associated proteins28. Moreover, nucleotide excision repair (NER), which repairs changes 
in DNA helical structure recognizing intra-strand crosslinks, has been implicated in 
mediating platinum-based drug resistance by way of cross-complementation group 1 
(ERCC1)28. It was reported that ERCC1 expression negatively correlated with patient 
survival and platinum therapy response, and knockout of ERCC1 increased sensitivity of 
platinum-resistant ovarian cancer cell lines28. It is possible that dysregulated repair 
mechanisms may explain acquired chemotherapy resistance by way of modification of 
downstream angiogenic genes. In support of this notion, gamma-histone H2A variant 
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H2AX (γ-H2AX) which is rapidly generated by DNA-damaging chemotherapeutic 
agents, is recently linked to angiogenesis and cancer progression93. 
5.2 Carboplatin induced upregulation of diverse angiogenic 
genes 
One of my key objectives was to answer the question: what specific subset of angiogenic 
factors are released by ovarian cancer cells and endothelial cells in response to 
carboplatin exposure? Remarkably, after carboplatin exposure, ovarian cancer cells and 
endothelial cells exhibited upregulation of a large number of angiogenic genes (Figure 
4.3.1, Figure 4.3.2, and Figure 4.3.3). There are a number of ways to digest this wealth 
of data. We could possibly examine genes which are induced in both ovarian cancer cell 
types or examine each induction individually. If examined individually, the variation may 
uncover tumour type-specific angiogenesis factors but would require the profiling of a 
large number of different ovarian cancer cell lines to provide meaningful results. We 
could also examine genes which are induced in both COV362 and COV318. In this case, 
the key factors include EFNA, F3, FGF1, IL1B, Il6, NOTCH4, PGF, S1PR1 and SPHK1. 
Among these are factors which have been targeted in a number of human cancers. For 
example, IL6 has been extensively studied in ovarian cancer and is known to be secreted 
by ovarian cancer cells and through inflammation94. In effect, IL6 and its receptor have 
shown to decrease the effectiveness of taxol-based chemotherapeutic agents on 
endothelial cell apoptosis and migration94,95. Both COV362 and COV318 cells showed 
increased expression of IL6 post-carboplatin exposure, which may contribute to the 
survival of endothelial cells seen in the condition media assay (Figure 4.4.1 and Figure 
4.4.2). IL6 has also shown to act upstream of MMP9 secretion96, and COV362 cells in 
my results reveal increased expression of both genes, which may contribute to overall 
tumorigenicity. 
In my studies, I also profiled endothelial cells to identify autocrine factors which may be 
involved in neovascularization following carboplatin treatment. Similar to ovarian cancer 
cells, carboplatin induced the expression of a number of genes including ANGPTL4, 
IFNA1, IL1B, IL8, PGF, PLAU, SERPINE1, TGFBR1, and VEGFA. Some of these 
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factors have also been targeted in clinical and preclinical studies even if the reasoning 
was that these may potentially be released by cancer cells. For instance, VEGFA and its 
tyrosine kinase receptors are the main targets to counteract tumour angiogenesis. Clinical 
trials are investigating VEGFA inhibitors such as Avastin and Ranibizumab combined 
with chemotherapy and results have shown improved progression-free survival (PFS) but 
unchanged overall survival rates in comparison to chemotherapy alone97. In addition, 
Avastin has shown to improve progression-free survival (PFS) with regular maintenance 
therapy77. However, the upregulation of other pro-angiogenic factors shows that anti-
VEGF therapies may not be enough to block angiogenesis98. Nevertheless, the reasons for 
varying responses to anti-VEGF therapy among some patients and tumour types remain 
unclear, and current research is turning to predictive biomarkers to distinguish patients 
that can benefit from anti-VEGFA therapies17,97. 
A limitation in my studies is the emphasis on upregulation of angiogenic genes and not 
their downregulation including that of anti-angiogenic factors. A number of genes were 
shown to be significantly decreased after carboplatin exposure in my studies (data not 
shown). As the balance between pro- and anti-angiogenic factors dictates the angiogenic 
switch, examining anti-angiogenic factors may further expose changes that take place 
post-carboplatin exposure in the tumour microenvironment. 
5.3 PGF as a potential mediator of carboplatin-induced 
angiogenesis  
PGF is reported to have controversial effects in cancer; highly expressed in some cancers 
such as gastric and breast carcinomas, but downregulated in others such as colon and 
lung carcinomas99. Also, the inhibition of PGF has shown to have antitumor and 
antiangiogenic effects in some cancers but again, not others99. Under physiological 
conditions, PGF is primarily known to be expressed in placenta; however, it is also 
expressed at low levels in other tissues such as the heart, lung, thyroid, skeletal muscle 
and adipose tissue100. PGF was shown to play a redundant role in vascular development 
and physiological vessel maintenance in healthy adults101. Yet, PGF is variably 
upregulated in tumours87 and it is stipulated to contribute to pathological angiogenesis in 
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a number of ways101. One way that PGF stimulates angiogenesis is through modulating 
VEGF, a crucial factor involved in stimulating endothelial cells as well as increasing 
permeability of microvasculature17,101. VEGFA can bind to both VEGFR1 and VEGFR2; 
meanwhile PGF binds primarily to VEGFR1. Binding of PGF to VEGFR1 limits VEGFA 
binding and displaces bound VEGFA because of higher affinity63. This, in turn, amplifies 
endogenous VEGFA signaling through VEGFR287. Signaling through VEGFR2 
promotes tyrosine residue phosphorylation, activating downstream 
RAS/RAF/ERK/MAPK pathway and the PI3K/AKT pathway, ultimately stimulating 
endothelial cell proliferation and survival respectively50. Also, though with weaker 
effects, PGF can initiate a similar angiogenic cascade by binding to VEGFR1, inducing 
phosphorylation of tyrosine residue Y1309, which is involved in stimulating the AKT 
pathway, enhancing signaling leading to neovascularization50. By phosphorylation of 
tyrosine residue Y784 and Y1169, PGF also promotes endothelial cell proliferation50. 
Furthermore, although with controversial evidence, PGF and VEGF may form 
homodimers and heterodimers contributing to endothelial cell mitogenic and chemotactic 
activity87,102. Figure 5.3.1 summarizes some of the important interactions regarding PGF 
and VEGF.  
Figure 5.3.1 PGF and VEGFA interactions. 
  
46 
 
Increased PGF and VEGFA have been shown to recruit monocytes/macrophages to 
cancer tissues to induce angiogenesis103. In monocytes, PGF has shown to initiate 
VEGFR1 phosphorylation to lead to the PI3K/AKT and MAPK (p38) pathways104. Thus, 
angiogenesis can be induced by the constitutive activation of the MAPK pathway via 
either VEGF receptors55. Carmeliet et al. (2001) found that even at low doses of PGF, 
impaired VEGF response in Pgf -/- mouse endothelial cells was restored, concluding that 
PGF and VEGFA have a synergistic effect during pathological angiogenesis87. 
Additionally, when VEGFA binds to VEGFR2, in concurrence with PI3K/AKT pathway 
activation, it rescues endothelial cells from drug-induced cell death55.  
VEGF is known to have strong expression in malignant tumours such as serous 
adenocarcinomas17. In this study, VEGF expression levels with or without carboplatin 
exposure in COV362 and COV318 cells did not show a significant difference. A possible 
explanation may be that if there is indeed strong initial VEGF expression in COV362 
and/or COV318 cells, it may contribute to tumour angiogenesis regardless of exposure to 
carboplatin. It is interesting to note that in this study, HDMECs have significantly 
elevated VEGFA mRNA levels post-carboplatin exposure. Taken together, carboplatin-
induced VEGFA in HDMECs may add to the overall enhancement of angiogenic 
stimulus. Alternatively, varying levels of angiogenic factors in endothelial cells and 
ovarian cancer cells may contribute differently to overall angiogenic balance. Parallel to 
my results, Kuc et al. (2017) evaluated expression of angiogenic genes in ovarian cancer 
and healthy patient ovarian samples and found no difference in VEGFA expression. 
Moreover, the researchers did not find a difference in the expression of PGF in control 
versus ovarian cancer patient samples54. To that end, my results may confirm that PGF 
expression is induced by carboplatin. In contrast, examination of resected ovarian cancer 
specimens compared to paired non-tumour ovarian tissue, Song et al. (2015) have found 
increased protein levels of PGF in the cancer specimens. It is important to note that in 
both studies, it is unclear whether these ovarian cancer patient specimens had prior 
treatment54,105. In addition, PGF has been shown to be elevated when anti-VEGF drugs 
are used106. Horowitz et al. (2011) explored the efficacy of multiple anti-angiogenic 
drugs in recurrent platinum-sensitive ovarian carcinoma patients and found that Avastin 
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in combination with chemotherapy resulted in increased levels of circulating VEGF and 
PGF. The researchers claimed however, that PGF and VEGF were released by the host 
cells and not by cancer cells107. My results show that PGF was induced in endothelial 
cells as well as ovarian cancer cells after carboplatin-based therapy. Taken together, it is 
possible that carboplatin-based therapy and anti-VEGF therapy may have dual effects on 
PGF expression in the tumour microenvironment. 
Interestingly, COV362 cell showed greater mRNA induction of PGF in comparison to 
COV318 cells after carboplatin exposure (Figure 4.3.2, Figure 4.3.3 and Table 4.3.1). 
Using ovarian cancer cell condition media, I tested the effects of carboplatin-induced 
angiogenic factors such as PGF on microvascular endothelial cell survival. Perhaps due 
to this higher induction of PGF, endothelial cells exposed to COV362-derived condition 
media showed significantly greater endothelial cell survival (Figure 4.4.1). Whereas, this 
effect was only evident when I tested a longer-term collection from COV318 cells 
(Figure 4.4.2). One explanation of differential induction of angiogenic factors in 
COV362 and COV318 may be CNA, which is quite high14. However, a recent study has 
shown that there were no copy number changes in PGF and IL1B1 in COV cells108.  
The main limitation of this study is the strict evaluation of gene expression profiles; 
further studies are required to confirm these genes by protein array assessment, possibly 
by enzyme-linked immunosorbent assay (ELISA). To that end, in this study, I have also 
explored the effects of human recombinant PGF and VEGFA (rPGF/rVEGFA). I found 
that there was an increase in endothelial cell viability with rVEGFA or rPGF, however 
rVEGFA had a greater effect on endothelial cell viability in comparison to exposure to 
rPGF alone (Figure 4.5.1). Also, there was no significant difference between HDMECs 
exposed to rVEGFA versus combination exposure of rPGF and rVEGFA. Taken 
together, rPGF and rVEGFA did not have a synergistic effect on endothelial cell survival 
and proliferation. One study found a synergistic effect, where upregulation of PGF and its 
receptor VEGFR1 made endothelial cells more responsive to VEGF87. Although 
synergism did not occur with rPGF and rVEGFA, it is important to note that endogenous 
PGF and VEGFA were not explored. 
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5.4 Inflammation, angiogenesis, and cancer: the role of 
IL1B 
The tumour microenvironment is complex, and cancer-related inflammation also 
promotes angiogenesis and tumorigenesis. A number of pro-inflammatory genes were 
upregulated after carboplatin treatment such as IL1B. IL1β is a cytokine that affects many 
inflammatory processes; it is an actively secreted mature protein product by macrophages 
and blood monocytes109. Recombinant IL1β has been shown to increase tumour invasion 
and metastasis by stimulating endothelial cell proliferation as well as enhancing the 
expression of adhesion molecules on endothelial and malignant cancer cells109. Voronov 
et al. (2003) have shown lack of melanoma tumour growth in IL1β knockout mice but 
dramatic growth in WT mice109. Previous studies also provide evidence that PGF initiates 
inflammation by binding to its receptor VEGFR1, which in turn recruits monocytes110. 
Kim et al. (2012) also show that fibroblasts produce PGF when exposed to pro-
inflammatory factors such as IL1B76.  Therefore, IL1B may potentially contribute to the 
propagation of PGF in the same manner in ovarian cancer. 
In addition, Bohm et al. (2016) explored the effect of neoadjuvant chemotherapy (NACT) 
on immune activation in late stage HGSOC patient samples and found that chemotherapy 
may enhance the cytotoxicity of immune effector cells111. T-cell activation as well as low 
plasma levels of proinflammatory cytokines like TNF, IL8 and IL6 were found after 
NACT111. In contrast, my results have shown significant increase in IL6 mRNA levels in 
ovarian cancer cells after chemotherapy exposure as well as elevated levels of IL8 in 
HDMECs. Further studies are needed to explore plausible roles of increased 
inflammatory cytokine expression in ovarian cancer cells post-carboplatin exposure. 
5.5 Wnt pathway activation via carboplatin may lead to 
downstream angiogenic effects 
My results show increased nuclear β-catenin and decreased membrane β-catenin in 
COV318 and COV362 cells following exposure to carboplatin (Figure 4.6.1 and Figure 
4.6.2). β-catenin activation is known to activate specific genes involved in cell 
proliferation and survival112. Normally, β-catenin is associated with cell membrane 
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cadherins and cytoplasmic levels are kept in check by phosphorylation and ubiquitin-
mediated proteosomal degradation89. Glycogen synthase kinase (GSK)-3 phosphorylates 
β-catenin, drawing in E3-ubiquitn ligase β-TrCP to initiate β-catenin degradation89. Upon 
activation of the Wnt pathway, cytoplasmic β-catenin levels increase. This may be due to 
reduced association with cadherins and/or reduced degradation113. Cytosolic β-catenin 
then translocates to the nucleus where it can initiate transcription of downstream genes89. 
β-catenin (CTNNB1) mutation frequencies are found to be between 16%114 and 54% in 
endometrioid cancers, however CTNNB1 mutations are rare in other ovarian cancer 
histological subtypes such as serous, clear cell and mucinous115,116. It is important to note 
that COV362 and COV318 ovarian cancer cell lines used in this study do not harbour a β-
catenin mutation, an interesting study would be to evaluate carboplatin-induced β-catenin 
localization in a mutated ovarian cancer cell line, such as OVCAR814, in relation to pro-
angiogenic activity. 
Chemoresistance is associated with acquiring epithelial to mesenchymal transition (EMT) 
in ovarian cancer cells and a major signaling pathway involved is the Wnt/β-catenin 
pathway116. In ovarian cancer, emerging studies have proposed that the Wnt/β-catenin 
pathway is involved in cancer progression116. The key components of EMT entails the 
loss of polarity and cell-to-cell adhesion junctions of epithelial cells and gain of 
mesenchymal gene expression and motility117. When the canonical Wnt pathway is 
activated, cytosolic β-catenin is stabilized and translocates to the nucleus to transcribe 
downstream target genes such as c-MYC, MMP, and VEGF116. Interestingly, COV362 
cells have amplified c-MYC, which may contribute to cell survival upon chemotherapy-
induced Wnt pathway activation14. It is possible that c-MYC expression and potential 
subsequent expression of pro-angiogenic factors may influence the outcomes of 
endothelial cell survival in comparison to COV318 cells which do not have amplified c-
MYC. Furthermore, Masckauchan et al. (2005) found that IL8 is a transcriptional target of 
β-catenin which promotes pro-angiogenic activity118. This aligns well with my results, 
where IL8 mRNA levels were elevated after carboplatin treatment (Figure 4.3.1). 
Another group showed that HGSOCs correlated with nuclear β-catenin expression119: 
Arend et al. (2014) reported that overexpression of oncogene frequently rearranged in 
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advanced T cell lymphomas-1 (FRAT1) in serous ovarian cancer inhibits the 
phosphorylation of β-catenin, eventually leading to its translocation to the nucleus.  
Little is known of the relationship between PGF, β-catenin and Wnt pathway signaling; 
therefore, this possible axis could be further explored in future studies. 
5.6 Concluding Remarks 
Ovarian cancer is the most lethal gynecological malignancy in Canada and a combination 
of late diagnosis and ineffective therapies potentially contributes to relapse or resistance 
in patients. Angiogenesis plays a key role in solid tumour progression and metastasis. 
Despite the use of anti-VEGF therapies in combination with chemotherapy for ovarian 
cancer, overall survival is minimally impacted. Therefore, more studies are needed to 
catalogue angiogenic genes which are induced in ovarian cancer and factors which show 
alteration upon chemotherapy exposure. My studies showed that carboplatin induced a 
variety of angiogenic factors in ovarian cancer cells. Most interestingly, PGF and IL1B 
were induced in all types tested and may therefore play a pivotal role in promoting 
angiogenesis in ovarian cancer. Carboplatin also induced Wnt pathway activation shown 
by nuclear β-catenin localization. It is possible that PGF is a downstream target of 
activated Wnt/β-catenin pathway and promotes angiogenesis after carboplatin exposure 
(Figure 5.6.1). 
Figure 5.6.1 Possible interactions between PGF, VEGF and β-catenin after 
carboplatin exposure. 
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5.7 Future Directions 
Further studies are needed to elucidate the possible interactions between the Wnt 
pathway/β-catenin activation with angiogenic factor PGF. Exploring PGF and β-catenin 
inhibition in carboplatin-resistant ovarian cancer cells may also provide insight into the 
utility of PGF and β-catenin as targets for patients encountering relapse. Another possible 
future direction may be to investigate the role of Wnt pathway and β-catenin 
transcriptional activity which may determine the differing responses of HGSOCs that 
resist chemotherapy or acquire chemotherapy resistance. 
It is also essential to identify possible angiogenic targets so that effective combination 
therapies can be devised. A cohort evaluation of multiple ovarian cancer cell lines may 
provide insight into tumour type-specific carboplatin-induced angiogenic factors. The 
evaluation of angiogenic factors post-chemotherapy patient samples exposure by gene 
expression profiling or by proteomic evaluation using mass spectrometry can also be 
essential. 
The angiogenic process primarily involves endothelial cell survival, proliferation, tubule 
formation and migration120. Further functional tests can be performed to elucidate the role 
of angiogenic factors post-carboplatin exposure and post-Wnt pathway activation. For 
instance, individual factors can be evaluated by functional assays to test tubule formation 
ability in vitro by three-dimensional tubule formation assay, or ex vivo by chick 
chorioallantoic membrane assay121. Scratch assays can be used to evaluate the migratory 
ability of endothelial cells in response to ovarian cancer cell carboplatin-induced 
angiogenic factors122. Knowing the mechanisms that govern tumour cell-to-host cell 
interactions in response to carboplatin may also provide additional targets. By co-
culturing ovarian cancer cells and endothelial cells with a particular gene of interest 
knocked out, the effect of possible interactions in regard to survival, proliferation, 
migration and tubule formation can be explored. 
Furthermore, many other cells that exist within the tumour environment also contribute to 
angiogenesis and consequently tumour survival120. Therefore, further studies elucidating 
in vivo pro-angiogenic response and cross-talk of angiogenic pathways induced by 
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carboplatin (in mouse tumour models123 for example) must be further investigated to 
include these dynamic cell interactions which may ultimately provide a better 
understanding of the tumour microenvironment in response to carboplatin therapy. 
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Appendix 
Appendix 1 RT2 Human Angiogenesis ProfilerTM PCR Array as prepared by Qiagen 
Symbol Description 
AKT1 V-akt murine thymoma viral oncogene homolog 1 
ANG Angiogenin, ribonuclease, RNase A family, 5 
ANGPT1 Angiopoietin 1 
ANGPT2 Angiopoietin 2 
ANGPTL4 Angiopoietin-like 4 
ANPEP Alanyl (membrane) aminopeptidase 
ADGRB1 Brain-specific angiogenesis inhibitor 1 
CCL11 Chemokine (C-C motif) ligand 11 
CCL2 Chemokine (C-C motif) ligand 2 
CDH5 Cadherin 5, type 2 (vascular endothelium) 
COL18A1 Collagen, type XVIII, alpha 1 
COL4A3 Collagen, type IV, alpha 3 (Goodpasture antigen) 
CTGF Connective tissue growth factor 
CXCL1 Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating 
activity, alpha) 
CXCL10 Chemokine (C-X-C motif) ligand 10 
CXCL5 Chemokine (C-X-C motif) ligand 5 
CXCL6 Chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) 
CXCL9 Chemokine (C-X-C motif) ligand 9 
EDN1 Endothelin 1 
EFNA1 Ephrin-A1 
EFNB2 Ephrin-B2 
EGF Epidermal growth factor 
ENG Endoglin 
EPHB4 EPH receptor B4 
ERBB2 V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian) 
F3 Coagulation factor III (thromboplastin, tissue factor) 
FGF1 Fibroblast growth factor 1 (acidic) 
FGF2 Fibroblast growth factor 2 (basic) 
FGFR3 Fibroblast growth factor receptor 3 
FIGF C-fos induced growth factor (vascular endothelial growth factor D) 
FLT1 Fms-related tyrosine kinase 1 (vascular endothelial growth 
factor/vascular permeability factor receptor) 
FN1 Fibronectin 1 
HGF Hepatocyte growth factor (hepapoietin A; scatter factor) 
HIF1A Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor) 
HPSE Heparanase 
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ID1 Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 
IFNA1 Interferon, alpha 1 
IFNG Interferon, gamma 
IGF1 Insulin-like growth factor 1 (somatomedin C) 
IL1B Interleukin 1, beta 
IL6 Interleukin 6 (interferon, beta 2) 
CXCL8 Interleukin 8 
ITGAV Integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) 
ITGB3 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
JAG1 Jagged 1 
KDR Kinase insert domain receptor (a type III receptor tyrosine kinase) 
LECT1 Leukocyte cell derived chemotaxin 1 
LEP Leptin 
MDK Midkine (neurite growth-promoting factor 2) 
MMP14 Matrix metallopeptidase 14 (membrane-inserted) 
MMP2 Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type 
IV collagenase) 
MMP9 Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type 
IV collagenase) 
NOS3 Nitric oxide synthase 3 (endothelial cell) 
NOTCH4 Notch 4 
NRP1 Neuropilin 1 
NRP2 Neuropilin 2 
PDGFA Platelet-derived growth factor alpha polypeptide 
PECAM1 Platelet/endothelial cell adhesion molecule 
PF4 Platelet factor 4 
PGF Placental growth factor 
PLAU Plasminogen activator, urokinase 
PLG Plasminogen 
PROK2 Prokineticin 2 
PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and 
cyclooxygenase) 
S1PR1 Sphingosine-1-phosphate receptor 1 
SERPINE1 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 1 
SERPINF1 Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment 
epithelium derived factor), member 1 
SPHK1 Sphingosine kinase 1 
TEK TEK tyrosine kinase, endothelial 
TGFA Transforming growth factor, alpha 
TGFB1 Transforming growth factor, beta 1 
TGFB2 Transforming growth factor, beta 2 
TGFBR1 Transforming growth factor, beta receptor 1 
THBS1 Thrombospondin 1 
THBS2 Thrombospondin 2 
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TIE1 Tyrosine kinase with immunoglobulin-like and EGF-like domains 1 
TIMP1 TIMP metallopeptidase inhibitor 1 
TIMP2 TIMP metallopeptidase inhibitor 2 
TIMP3 TIMP metallopeptidase inhibitor 3 
TNF Tumor necrosis factor 
TYMP Thymidine phosphorylase 
VEGFA Vascular endothelial growth factor A 
VEGFB Vascular endothelial growth factor B 
VEGFC Vascular endothelial growth factor C 
ACTB Actin, beta 
B2M Beta-2-microglobulin 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
HPRT1 Hypoxanthine phosphoribosyltransferase 1 
RPLP0 Ribosomal protein, large, P0 
HGDC Human Genomic DNA Contamination 
RTC Reverse Transcription Control 
RTC Reverse Transcription Control 
RTC Reverse Transcription Control 
PPC Positive PCR Control 
PPC Positive PCR Control 
PPC Positive PCR Control 
. 
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factors in ovarian cancer 
• Authors: ZG Kahramanoglu, MM Weir, ZA Khan 
 
03/2017 Pathology and Laboratory Medicine Research Day, London, 
ON. 
• Abstract: Carboplatin paradoxically increases angiogenic 
factors in ovarian cancer 
• Authors: ZG Kahramanoglu, MM Weir, ZA Khan 
 
10/2016  Till and McCulloch Meetings, Whistler, BC. 
• Abstract: Mechanisms underlying chemotherapy-induced 
hematopoietic stem cell deficits and myelosuppression 
• Authors: ZG Kahramanoglu, MM Weir, ZA Khan 
 
06/2016  Oncology Research and Education Day, London, ON. 
• Abstract: Mechanisms underlying chemotherapy-induced 
vascular proliferation in ovarian cancer 
• Authors: ZG Kahramanoglu, MM Weir, ZA Khan 
 
05/2016  Annual Developmental Biology Research Day, London, ON. 
• Abstract: Mechanisms underlying chemotherapy-induced 
vascular proliferation in ovarian cancer 
• Authors: ZG Kahramanoglu, JJY Kum, NC Richmond, 
MM Weir, ZA Khan 
 
03/2016 Pathology and Laboratory Medicine Research Day, London, 
ON. 
• Abstract: Mechanisms underlying chemotherapy-induced 
vascular proliferation in ovarian cancer 
• Authors: ZG Kahramanoglu, MM Weir, ZA Khan 
 
03/2016  London Health Research Day, London, ON. 
• Abstract: Mechanisms underlying chemotherapy-induced 
vascular proliferation in ovarian cancer 
• Authors: ZG Kahramanoglu, MM Weir, ZA Khan 
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04/2014  College of Biological Science Research Day, Guelph, ON. 
• Abstract: Optimization of the clonogenic cell survival in vitro 
assay for the study of chemotherapy response of 
osteosarcoma cells 
• Authors: ZG Kahramanoglu, A Viloria-Petit 
 
07/2013 Institute for Comparative Cancer Investigation Research 
Symposium, Guelph, ON. 
• Abstract: The role of transcriptional co-activator PDZ-
binding motif (TAZ) in osteosarcoma metastasis 
• Authors: ZG Kahramanoglu, P Neogi, B Deheshi, A 
Viloria-Petit 
 
07/2013 Student Leadership and Research Program Symposium, 
Guelph, ON. 
• Abstract: The role of stem cell transcription factors in 
osteosarcoma metastasis 
• Authors: ZG Kahramanoglu, P Neogi, B Deheshi, A 
Viloria-Petit 
 
07/2012  Research Training Center Summer Program Research Day,  
Toronto, ON. 
• Abstract: Molecular validation of copy number variation in 
osteosarcoma 
• Authors: ZG Kahramanoglu, N Gokgoz, I Andrulis.  
  
 
 
RELATED WORK EXPERIENCE 
 
09/2016 - 12/2016 Graduate Teaching Assistant, Department of Basic Medical 
Sciences Undergraduate Education, Western University, London, 
ON.  
• Course code: MEDSCI 4930 
 
01/2015 - 08/2015 Research Technical Assistant, University Health Network, 
Toronto, ON. 
 
05/2013 - 08/2013 Undergraduate Research Assistant, Department of Biomedical  
   Sciences, University of Guelph, Guelph, ON. 
 
05/2012 - 08/2012 Research Training Center Summer Student, Lunenfeld-
Tanenbaum Research Institute, Toronto, ON.  
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AWARDS 
 
04/2017 Dr. Frederick Winnett Luney Graduate Research Award, 
UWO 
 
2015 - 2017  Western Graduate Research Scholarship, UWO 
 
11/2016 Ontario Institute for Regenerative Medicine Travel Award, 
OIRM 
 
 
 
DEPARTMENAL & COMMUNITY ACTIVITIES 
 
09/2015 - present Research Information Outreach Team (R.I.O.T), London 
• Notably: Host/Guide for Virtual Lab Tours YouTube 
series, Young Researchers series (Author, The 
Londoner (06/2017 Article) and Interviewee for Rogers 
Television) 
• “Let’s Talk Cancer” event volunteer, program designer 
and organizing committee member (05/2016 and 
05/2017) 
 
10/2016 - present Strong Bones, Strong Minds, Strong Muscles, Western 
University 
• Scientific education presenter in retirement homes 
• Fundraising volunteer 
 
11/2015 - present Let’s Talk Science, Western University 
• Presented scientific concepts to individuals ranging 
from grade 1- 12 in fun science-related activities; 
volunteer with the “Teacher Partnership Program” 
• Mentor for Grade 10 Interdisciplinary Research Project 
 
11/2015 - present CHRW Radio, Western University 
• Morning show host for Wake Up Western 
• Writer, editor and on-air presenter for Morning News 
 
09/2015 - present Canadian Cancer Society, Elgin Middlesex Community Office, 
London 
• Notably: Scientific Research Presenter for 2016 
Volunteer Appreciation events for London, and 
Chatham-Kent, ON. 
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12/2016 - 04/2017 Stem Cell Talks, Western University 
• Youth education event volunteer 
 
03/2016 & 03/2015 SciNapse, Western University 
• Poster judge; mentored and encouraged students to 
apply critical thinking 
